The new manufacturing facility and the laboratory, which were developed with a €12m investment, were unveiled yesterday by Roger Connor, GSK’s global manufacturing supply president, and by Joe Power, GSK Cork site director.
The company says the new, €9.5m kilo scale facility will enable the site to begin manufacturing highly specialised, active ingredients for newer, targeted oncology medicines.
Meanwhile, GSK says the new technical development laboratory, built for €2.5m, will widen the range of pharmaceuticals it can produce, including treatments for diseases such as cancer, HIV, and depression.
The global healthcare company employs 1,800 staff in Ireland, in Cork, Dublin, Waterford and Sligo. It has 450 employees in Cork, where it has had a base for 41 years. Kevin O’Keefe, head of engineering at GSK Cork, said the kilo scale facility was a new opportunity for GSK in Cork. “The plant will expand our operating scale to allow us introduce new, targeted medicines that require highly specialised manufacturing equipment. This investment opens up new potential for Cork to produce these in the future,” he said.
GSK site director, Joe Power, described the investment as “substantial” and said it “demonstrates GSK’s strong commitment to our Cork site.”
“It’s a wonderful endorsement of the world-class technical capability we have here, and will work to attract new business for the operation,” Mr Power said.
“It will also be very rewarding for our employees, knowing the difference they will be making to patients all over the world, who will ultimately take the medicines that started out here in Cork.” GSK said it had now invested €700m in the Cork site, since it opened in 1974, and that it had invested €30m in R&D in Ireland last year alone.
Earlier in the week, the company announced its second, annual IMPACT Awards, which have been designed “to recognise and reward community-based charities, who contribute to the improvement of people’s health and well-being in Ireland.”
“GSK wants to champion these charities, so many of whom are at the heart of Irish community health,” Claire Taaffe, communications director for GSK, said.